Our stories highlight the impact of our work on people’s lives and how access to affordable quality treatment brings hope and a future. Our work is for people, and in all that we do, we keep the needs of the end user in mind. Through this section, we share the voices of our partners on our joint mission to make sure no one is left behind.
Tuberculosis is consistently in the top three communicable pathogens globally. In 2021, MPP signed a licence agreement with Tandem Nano Ltd., the University of Liverpool start-up focused on the development of its proprietary long-acting nanosystems [LG1] platform technology. There is much excitement in the tuberculosis treatment community about the potential of this long-acting medicine, with several members […]
04 December 2025
Keyword